Blocking the mineralocorticoid receptor has been proposed and validated as an additional tool: clinical studies in patients with severe or mild heart failure demonstrated an additional benefit of MRAs administered on the top of standard therapy [8]–[10]. The gene discussed is NR3C2; the disease is heart failure.